To date, all efforts to develop a disease-modifying treatment
|
|
- Rudolf Elvin Gregory
- 5 years ago
- Views:
Transcription
1 After Disappointments, Alzheimer s Researchers Seek Out New Paths Biomarkers and Combination Therapies May Lead To Disease-Modifying Treatments, Experts Say Susan Worley John Trojanowski, MD, PhD To date, all efforts to develop a disease-modifying treatment for Alzheimer s disease (AD) have been unsuccessful. Consequently, the treatments available to address the disease treat only the symptoms (Table 1). However, the many clinical trials that have ended in disappointment may yet prove to have a silver lining, as a critical and collaborative re-examination of premises that guided earlier research is taking place in their aftermath. Experts have long agreed on two primary neuropathological hallmarks of AD: beta-amyloid (Aβ) plaques and hyperphosphorylated tau in the form of neurofibrillary tangles, both of which are present in the brains of individuals with AD. Most efforts to develop a disease-modifying treatment have focused on Aβ-related interventions. Reports on phase 3 trials of two such interventions, anti-aβ antibodies bapineuzumab (Janssen/ Pfizer) 1 and solanezumab (Eli Lilly), 2 which involved more than 4,000 patients, appeared in a January 2014 issue of the New England Journal of Medicine. Both agents were tested in patients with mildto-moderate AD, and although both successfully reached their targets and showed evidence of clearing or modifying Aβ deposits in the brain, neither agent significantly improved clinical outcomes in AD patients. Among the lessons learned from these and other failed clinical trials, including those of an active anti-aβ vaccine, 3 John Trojanowski, MD, PhD, Director of the Institute on Aging and the Alzheimer s Disease Core Center at the University of Pennsylvania, says three are most important. First, we know that we must intervene at an earlier stage of the disease, Dr. Trojanowski says, so it is now essential to design prevention trials or clinical trials that address prodromal AD. Second, we must use biomarkers in all patient populations to increase confidence in diagnosis and also to monitor target engagement, as well as response to therapy. And third, we must develop drugs that address other AD targets, such as tau tangles. Reisa Sperling, MD, Director of the Center for Alzheimer s Research and Treatment at Brigham and Women s Hospital and Massachusetts General Hospital and Professor of Neurology at Harvard Medical School, cites these same lessons, with an emphasis on the need to treat the right target at the right stage of disease. 4 Phase 3 trials with both bapineuzumab and solanezumab suggest that it s more likely that we will have success with antiamyloid therapies at earlier stages of the disease, Dr. Sperling says. The solanezumab trials, in particular, showed a benefit in patients with mild dementia, but none of the studies shows statistically significant effects clinically or on biomarkers in the moderate dementia groups. Another lesson we learned is that we need to be able to give enough of these antibodies to increase binding enough to remove amyloid. In the bapineuzumab studies, dosing was limited by side effects; that wasn t true in the solanezumab studies, which may be why they were able to see some evidence of a clinical effect in a subgroup. Rethinking AD pathophysiology Puzzling to many inside and outside of the field of AD research is the fact that some individuals with significant beta-amyloid accumulation can remain cognitively normal. 5,6 Moreover, studies have shown that AD-like neurodegenerative patterns can occur in patients without any beta-amyloid accumulation. 7 We don t have all the answers about amyloid yet and we don t yet have enough data, says Dr. Sperling, But the preponderance of data so far suggests that people who have evidence of amyloid accumulation over time show a faster rate of decline than people who do not. That does not mean that everyone with amyloid accumulation will develop Alzheimer s disease, she adds. Most likely there are factors that confer resistance to amyloid, and as with high cholesterol and heart disease, amyloid most likely is only one part of the AD puzzle. We know, for example, that the vast majority who have high cholesterol will never have a heart attack or stroke, so cholesterol is only one contributing factor to heart disease. Even if amyloid is only a contributing factor to Alzheimer s disease, intervening at the right stage may prove to be beneficial, Dr. Sperling says. I do think there are many other factors to consider, some of which may prove to be synergistic among individuals who are amyloid positive. For example, for a given amount of amyloid, we know that APOE4 [the gene apolipoprotein Ε4] can further influence the rate of cognitive decline. Although it is well established that amyloid accumulation occurs early in the AD process, 8 most experts agree that it is only part of the puzzle, in part because its correlation with cognitive decline and disease progression so far remains weak. The cascade hypothesis posits that Aβ in some way trig- Susan Worley is a freelance medical writer who resides in Pennsylvania. Disclosure: The author reports that she has no commercial or financial relationships in regard to this article. Vol. 39 No. 5 May 2014 P&T 365
2 Table 1 Current Treatments for Symptoms The FDA has approved five treatments for symptoms of Alzheimer s disease, but one of them, tacrine (Cognex, Sciele Pharma) has been discontinued in the U.S. Use of these interventions can result in moderate but temporary improvement in cognitive function in individuals with mild-tomoderate dementia. Generic Name (Brand) Manufacturer Postulated Mechanism of Action Approximate Cost for 30 Days 24 Galantamine (Razadyne) Rivastigmine (Exelon) Janssen Pharmaceuticals Novartis Pharmaceuticals Enhances cholinergic function by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. The effect of galantamine may diminish with disease progression, as fewer cholinergic neurons remain functionally intact. 25 Enhances cholinergic function by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. The effect of rivastigmine may diminish with disease progression, as fewer cholinergic neurons remain functionally intact. 26 Donepezil (Aricept) Eisai Enhances cholinergic function by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. 27 Memantine (Namenda) Forest Pharmaceuticals N-methyl-D-aspartate (NMDA) receptor antagonism; memantine preferentially binds to the NMDA receptoroperated cation channels. 28 $265 to $550 depending on dosage and formulation $310 $340 to $380 depending on dosage and formulation $290 gers tau pathology, says Dr. Trojanowski, but solid evidence for this has been lacking since the earliest articulation of this hypothesis. We still do not have any studies to support the idea that shutting down Aβ might affect tau pathology. Perhaps there will be a benefit in the earliest stages of the disease; shutting down Aβ may attenuate or block the progression of some of the other pathologies in Alzheimer s disease, including tangles, Lewy bodies, and [protein] TDP-43 we don t know for sure. Suppressing the plaques at an early stage also could result in a transient effect; it s possible there could be a plateau for a year or more, and then the disease could come back with a vengeance because of the spread of the other pathologies. It s important to continue to pursue other targets, Dr. Trojanowski adds. I think combination therapy is the way of the future, and tend to agree with colleagues who say that we are now witnessing the last of the era of the monotherapy clinical trials. An initial resistance to the idea of combination therapy existed in other therapeutic areas, in cancer and AIDS, for example, and yet, particularly for AIDs, it has turned out to be the winning strategy. Indeed, Dr. Sperling, who is co-lead investigator of the A4 trial (see Current Clinical Trials later in this article) intends to pursue non amyloid as well as amyloid targets, expecting that the A4 trial design will serve as a platform for future secondary prevention trials with other agents, and ultimately for combinations of agents. 9 In addition, individuals screened for the trial who do not show evidence of elevated amyloid accumulation may be eligible to participate in LEARN, a companion observational study. The LEARN Reisa Sperling, MD study will seek to quantify amyloid-related cognitive decline and obtain data on nonamyloid factors that contribute to AD. Imaging Techniques and Nonimaging Biomarkers Because a successful treatment for AD may require intervention prior to the emergence of symptoms, early identification of pathology that indicates an increased likelihood of developing AD dementia is critical. Imaging and nonimaging biomarkers, as well as genetic information, are necessary to improve the sensitivity and specificity of all assessments, from those undergone at presymptomatic stages of the disease to those associated with the monitoring of treatment. The field has seen remarkable growth in all of these areas. We now have three FDA-approved amyloid imaging agents, including florbetapir (Amyvid, Avid Radiopharmaceuticals, approved in 2012) 10 followed by flutemetamol (Vizamyl, GE Healthcare) and florbetaben (Neuraceq, Piramal Imaging), that build on the foundation of the research tracer [11C] Pittsburgh Compound B (PiB) 11 for the detection of cerebral amyloid burden in individuals with cognitive changes, says Andrew Saykin, PsyD, ABCN, Director of the Indiana Alzheimer Disease Center at Indiana University School of Medicine and Genetics Core Leader at the Alzheimer s Disease Neuroimaging Initiative (ADNI). These F18-labeled PET [positron-emission tomography] tracers are an important improvement over the first generation of experimental amyloid tracers labeled with C11, which has a very short half-life. Another major development has been the standardiza- 366 P&T May 2014 Vol. 39 No. 5
3 tion of quantitative MRI [magnetic resonance imaging] markers, particularly for morphometric analysis of the integrity of structures such as the entorhinal cortex and hippocampus [Figure 1], which are affected early, as well as for assessing cortical thickness, Dr. Saykin says. These atrophy measures previously required very time-consuming manual measurements and now can be estimated using sophisticated software packages. Also important are advanced MRI techniques 12 such as diffusion tensor imaging, resting state, and task-based functional MRI, arterial spin labeling perfusion, and MR spectroscopy, all of which provide complementary mechanistic data. While all of these noninvasive MRI techniques have proven to be sensitive to early stages of disease, it is not yet clear which ensemble of techniques will be most reliable, informative, and predictive as a biomarker for AD. New developments in the realm of tau imaging, 13,14 although still in the early stages, also have been very encouraging. Many outside of the field, including patients and their families, hope that sophisticated imaging techniques may eventually replace the more invasive collection of cerebrospinal fluid (CSF) via lumbar puncture, but for now researchers still depend on CSF assays. Advances in imaging already provide noninvasive means for detecting AD-related changes or heightened risk for progressive cognitive decline, says Dr. Saykin. However, as with all methods, imaging has limitations. For example, despite the great progress in PET tracers for amyloid and tau, PET cannot yet detect several other important proteins that cause Andrew Saykin, PsyD, ABCN neuro degenerative changes leading to other forms of dementia. Unlike CSF, where multiplex assays can search for a range of abnormal proteins, in most cases PET scans are limited to a single molec ular target, such as amyloid plaque. Usually only one or two PET scans are administered to minimize radiation exposure. Imaging can provide information that is significantly more detailed when used in conjunction with genetic information and nonimaging biomarkers. Different biomarkers are likely to be more useful at particular stages of disease or in screening different at-risk groups, Dr. Saykin says. Once AD is detected during the early preclinical or prodromal phases, prior to extensive neurodegenerative changes, imaging can serve as a longitudinal biomarker to monitor response to therapy. Imaging and other approaches such as CSF analysis and genetics provide complementary information when used in combination. Our group and others have reported, for example, that PET, MRI, CSF, and plasma biomarker results are all significantly influenced by variation in APOE and other genes. Progress in the development of blood-based biomarkers, 15 which is occurring at a very rapid pace, 16 is tempered somewhat by the need for validation. There is a critical need for inexpensive and noninvasive biological markers to improve early detection and diagnosis of AD, says Maria Carrillo, PhD, Vice President of Medical and Scientific Relations at the Alzheimer s Association. Blood-based biomarkers with the potential for widespread clinical use will need to be validated in large groups of subjects who are represen- Healthy Brain Cerebral cortex Severe Alzheimer s Disease Ventricles Ventricles Hippocampus Entorhinal cortex Figure 1 A Healthy Brain Compared to One With Advanced Alzheimer s Disease This illustration shows the effects of advanced Alzheimer s disease on the brain. The cerebral cortex, entorhinal cortex, and hippocampus shrink dramatically, damaging areas responsible for cognition and memory. Fluid-filled ventricles become larger. Source: National Institute on Aging Vol. 39 No. 5 May 2014 P&T 367
4 tative of a diverse aging population, and the gathering, storage, and processing of such biomarkers must be standardized for dependability of use and consistent interpretation of results. An International Society to Advance Alzheimer s Research and Treatment (ISTAART) professional interest area (PIA) is creating standards and guidelines for the development of novel blood biomarkers and intends to validate them for use in research settings, clinical trials, diagnostics, and clinical practice. This ISTAART PIA also is developing a central data repository and sample bank network. A blood test for determining cholesterol levels is now available almost anywhere in the world, Dr. Carrillo says, and there are recognized standards for how and when to take the blood, how to process it, and how to interpret the results. The ISTAART PIA will help develop similar standards for AD biomarkers, so that eventually simple predictive and diagnostic tests can be effectively implemented. Current Clinical Trials Current clinical trials, characterized by a new focus on secondary prevention, involve the testing of populations comprising asymptomatic individuals at risk of developing AD, presymptomatic individuals with AD-related mutations, and/or individuals with prodromal AD. The Collaboration for Alzheimer s Prevention (CAP) consortium facilitates collaborative interactions among the first four of the following trials to maximize translatable findings. The Food and Drug Administration and European Medicines Agency, with input from CAP, issued guidance to assist these trials in pursuing an innovative regulatory pathway. 17 The A4 Study The Anti-Amyloid Treatment in Asymptomatic Alzheimer s Disease (A4) study 9 is a three-year, placebo-controlled, randomized clinical trial that will screen 5,000 clinically normal older individuals to identify and enroll 1,000 with increased amyloid accumulation on PET imaging, who are thus at increased risk for cognitive decline. Individuals enrolled in the first trial will be randomized to receive solanezumab or placebo; screened individuals who do not show evidence of elevated amyloid accumulation may be eligible to participate in the LEARN study, a companion observational arm that will run parallel to the A4 treatment arm with identical cognitive assessments. A4 and LEARN study participants will be followed for 168-week treatment and observation periods. Investigators anticipate that the A4 trial design will serve as a platform for secondary prevention trials with other anti-amyloid agents, such as betasecretase inhibitors, and for combinations of agents. The DIAN-TU Study In 2012, the Dominantly Inherited Alzheimer s Network Trials Unit (DIAN-TU) 18,19 launched a phase 2/3, randomized, double-blind, placebo-controlled, multicenter study of solanezumab or gantenerumab (Hoffman-LaRoche) in individuals at risk for dominantly inherited AD. A total of 210 participants with presenilin 1, presenilin 2, or amyloid precursor protein Maria Carrillo, PhD (APP) mutations have been assigned to receive solanezumab or gantenerumab in a phase 2 trial that may last up to two years. If biomarker endpoints are successfully met in the phase 2 trial, participants will make a seamless transition to a phase 3 trial (the DIAN-TU Adaptive Prevention Trial) with a cognitive endpoint and an expected total enrollment of 400 participants. Presenilin 1, presenilin 2, and APP mutations are rare, and individuals with these mutations together account for less than 1 percent of all individuals who develop AD. The goal of the DIAN-TU trials is to use biomarkers of target engagement, such as amyloid PET and CSF amyloidbeta measures, in addition to downstream biomarkers, including CSF tau, phospho-tau, MRI structural atrophy, functional MRI, PET with [18F]-fluorodeoxyglucose, and tau PET imaging, to track changes in the brains of individuals with these gene mutations who have not yet developed AD. The trial will also seek to test drugs that may slow or halt disease-related changes and possibly prevent the emergence of symptoms such as memory loss. The DIAN-TU trial platform is evaluating additional drugs to test in registration trials with built-in seamless transitions from biomarker to cognitive endpoints. The API ADAD Study The Alzheimer s Prevention Initiative (API) Autosomal Dominant Alzheimer s Disease (ADAD) trial is one of the first prevention trials conducted in cognitively healthy individuals who are certain to develop AD because of their genetic background. This study will include approximately 300 people from a large extended family in Colombia who share risk for a rare genetic mutation that typically triggers AD symptoms around age ,21 Participants in the double-blind, placebo-controlled trial will receive an injection of either crenezumab (Genentech/ AC Immune) or a placebo at set intervals for up to five years. The study will test whether crenezumab can protect participants in the short or long term from developing signs of AD. Using targeted biomarkers, state-of-the-art imaging, and sophisticated cognitive measures which allow researchers to detect and track the disease presymptomatically researchers will be able to see whether the amount of amyloid in the brain decreases, whether brain size is maintained, and, most importantly, whether cognitive function is preserved. In addition, to better understand the natural process of early-onset autosomal-dominant AD, researchers will compare changes in clinical symptoms and signs over time in people with and without the mutation who are treated with a placebo. Following the completion of the trial, efficacy and biomarker data and findings will be shared with the entire research community. The TOMMORROW Trial The TOMMORROW trial is designed to test the effectiveness of pioglitazone (AD-4833; Takeda), a drug already FDAapproved to treat type-2 diabetes, in the prevention of AD in individuals at risk for the disease. It also will examine the degree to which the TOMM40 risk allele confers a greater 368 P&T May 2014 Vol. 39 No. 5
5 placebo, based on comparisons of cognitive decline, functional decline, and changes in activities of daily living. Approximately 5,800 asymptomatic individuals between the ages of 65 and 83 years will be screened with the goal of enrolling about 120 participants at each of approximately 50 sites. All participants will undergo a blood test to establish APOE and TOMM40 genotypes. Cognitively normal individuals determined to be at high risk for developing AD will be randomized to receive either AD-4833 or placebo, and those in the treatment group will receive AD-4833 orally once per day. The SNIFF Study The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF) is a multicenter, double-blind, placebo-controlled phase 2/3 trial sponsored by the Alzheimer s Disease Cooperative Study to evaluate the impact of inhaled insulin in participants with mild memory impairment and early AD. 23 In this 18-month study, approximately 240 people ages 55 to 85 years will be given either intranasal insulin (INI) or placebo for 12 months, followed by an open-label six-month period during which all participants will receive INI. Some evidence indicates that insulin performs multiple functions in the brain and that insulin dysregulation may contribute to AD pathogenesis. INI has shown promise in short-term clinical trials. Conducted at 29 locations, SNIFF will examine INI s effects on cognition, entorhinal cortex and hippocampal atrophy, and CSF biomarkers. The study aims to examine whether baseline AD biomarker profile, gender, or the presence of the APOE4 allele predict treatment response. Figure 2 A Healthy Neuron Versus a Diseased Neuron Illustrations of a healthy neuron (above) and a diseased neuron (below). In Alzheimer s disease, many neurons stop functioning, lose connections with other neurons, and die. Alzheimer s disrupts processes vital to neurons and their networks, including communication, metabolism, and repair. Source: National Institute on Aging chance of developing AD. 22 In this five-year, phase 3, double-blind, placebo-controlled study, researchers will examine whether pioglitazone s ability to regulate glucose metabolism and insulin sensitivity and reduce inflammation will have a protective effect that is sufficient to prevent high-risk patients from developing mild cognitive impairment and AD. Pioglitazone s efficacy in delaying the onset of AD in cognitively normal individuals will be compared with Conclusion During the past decade, clinical trials that have focused on strategies for reducing the production and accumulation of Aβ in the brains of individuals with AD have offered valuable information. They have launched a new era of AD prevention trials, in which the pursuit of methods for modulating Aβ levels will be accompanied by the use of novel biomarkers that should offer greater insights into the role that Aβ plays in the disease process. Knowledge gleaned from these trials also has begun to inform the development of drugs that address nonamyloid targets, including at least one that involves a creative method for crossing the blood brain barrier, 23 and most likely will continue to inform research that ultimately moves in the direction of combination therapy. REFERENCES 1. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer s disease. N Engl J Med 2014;370(4): Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer s disease. N Engl J Med 2014;370(4): Vellas B, Black R, AN1792 (QS-21)-251 Study Team, et al. Longterm follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009;6(2): Sperling RA, Jack CR, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med 2011;3(111):111cm Arnold SE, Louneva N, Cao K, et al. Cellular, synaptic, and biochemical features of resilient cognition in Alzheimer s disease. Neurobiol Aging 2013;34(1): continued on page 374 Vol. 39 No. 5 May 2014 P&T 369
6 Alzheimer s Researchers Seek New Paths continued from page Negash S, Wilson RS, Leurgans SE, et al. Resilient brain aging: characterization of discordance between Alzheimer s disease pathology and cognition. Curr Alzheimer Res 2013;10(8): Wirth M, Villeneuve S, Haase CM, et al. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 2013;70(12): Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer s disease: a prospective cohort study. Lancet Neurol 2013;12(4): Sperling RA, Rentz DM, Johnson KA, et al. Stopping AD before symptoms begin? Sci Transl Med 2014;6(228):228fs Doraiswamy PM, Sperling RA, Johnson K, et al. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Molecular Psychiatry [published online ahead of print March 11, 2014] doi: /mp Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer s disease with Pittsburgh Compound-B. Ann Neurol 2004;55(3): Risacher SL, Saykin AJ. Neuroimaging and other biomarkers for Alzheimer s disease: the changing landscape of early detection. Annu Rev Clin Psychol 2013;9: Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013;79(6): Xia CF, Arteaga J, Chen G, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer s disease. Alzheimers Dement 2013:9(6): Snyder HM, Carrillo MC, Grodstein F, et al. Developing novel blood-based biomarkers for Alzheimer s disease. Alzheimers Dement 2014;10(1): Mapstone M, et al Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 2014; doi: / nm Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer s disease. N Engl J Med 2013;368(13): Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer s disease. N Engl J Med 2012;367(9): Moulder KL, Snider BJ, Mills SL, et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimer s Res Therapy 2013;5(5): National Institutes of Health. A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer disease, including a placebo-treated noncarrier cohort. Available at: NCT Accessed April 14, Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer s disease in the presenilin 1 E280A kindred: A case-control study. Lancet Neurol 2012;11(12): National Institutes of Health. Biomarker qualification for risk of mild cognitive impairment (MCI) due to Alzheimer s disease (AD) and safety and efficacy evaluation of pioglitazone in delaying its onset. Available at: Accessed April 14, National Institutes of Health. The study of nasal insulin in the fight against forgetfulness (SNIFF). Available at: gov/show/nct Accessed April 14, Red Book Online. Ann Arbor, Michigan; Truven Health Analytics. Accessed April 2, Razadyne, prescribing information. Titusville, New Jersey; Janssen Pharmaceuticals; Exelon, prescribing information. East Hanover, New Jersey; Novartis Pharmaceuticals; Aricept, prescribing information. Woodcliff Lake, New Jersey; Eisia Inc.; Namenda, prescribing information. St. Louis, Missouri; Forest Laboratories; n 374 P&T May 2014 Vol. 39 No. 5
ALZHEIMER'S DISEASE PREVENTION TRIALS
ALZHEIMER'S DISEASE PREVENTION TRIALS Laurie Ryan, PhD Chief, Dementias of Aging Branch & Program Director, Alzheimer s Disease Clinical Trials Division of Neuroscience National Institute on Aging/National
More informationStephen Salloway, M.D., M.S. Disclosure of Interest
Challenges in the Early Diagnosis of Alzheimer s Disease Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University 2 nd Annual Early Alzheimer s Educational
More informationMild Cognitive Impairment Symposium January 19 and 20, 2013
Highlights of Biomarker and Clinical Outcomes in Recent AD Treatment Trials Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University Mild Cognitive Impairment
More informationUnderstanding Symptoms, Causes, and Risks for Alzheimer s Disease
Understanding Symptoms, Causes, and Risks for Alzheimer s Disease Gene E. Alexander, Ph.D., Professor of Psychology, Neuroscience, and Physiological Sciences; Director, Brain Imaging, Behavior & Aging
More informationAlzheimer s Disease Update: From Treatment to Prevention
Alzheimer s Disease Update: From Treatment to Prevention Jeffrey M. Burns, MD Edward H. Hashinger Professor of Medicine Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science
More informationTammie Benzinger, MD, PhD
Tammie Benzinger, MD, PhD benzingert@wustl.edu Disclosure: Tammie L.S. Benzinger, M.D., Ph.D. Research Support / Grants: NIH/NIA 5P01AG026276, 1U01AG032438, AG003991-27, 1R01NS066905-01, 1P01NS059560-01A1,
More informationFact Sheet Alzheimer s disease
What is Alzheimer s disease Fact Sheet Alzheimer s disease Alzheimer s disease, AD, is a progressive brain disorder that gradually destroys a person s memory and ability to learn, reason, make judgements,
More informationBioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018
Press release BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018 Stockholm, Sweden, July 25, 2018 BioArctic AB (publ) (Nasdaq Stockholm:
More informationImaging of Alzheimer s Disease: State of the Art
July 2015 Imaging of Alzheimer s Disease: State of the Art Neir Eshel, Harvard Medical School Year IV Outline Our patient Definition of dementia Alzheimer s disease Epidemiology Diagnosis Stages of progression
More informationClaims & Underwriting. You already told us that story! Maria C. Carrillo, Ph.D. Sr. Director, Medical & Scientific Relations Alzheimer s Association
Claims & Underwriting Alzheimer s & Cognitive Impairment: You already told us that story! Maria C. Carrillo, Ph.D. Sr. Director, Medical & Scientific Relations Alzheimer s Association 1 OVERVIEW Impact
More informationAlzheimer s Disease. Fact Sheet. Fact Sheet. Fact Sheet. What Causes AD?
2 Alzheimer s Disease Dementia is a brain disorder that seriously affects a person s ability to carry out daily activities. The most common form of dementia among older people is Alzheimer s disease (AD),
More informationA perspective on preclinical Alzheimer's disease trials
A perspective on preclinical Alzheimer's disease trials Pierre N. Tariot, MD Director, Banner Alzheimer s Institute Co-Director, API Research Professor of Psychiatry University of Arizona Disclosures I
More informationMemory Matters: Learning Objectives: Synapses, Age, and Health. Neuronal Synapses DISCLOSURE DECLARATION. Cognition and Normal Aging
Standard Deviations from Mean Memory Matters: Preventing and Treating Late-Life, Cognitive Decline Daniel L. Murman, MD, MS Director, Behavioral and Geriatric Neurology Program Professor & Vice Chair,
More information8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research
The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event
More informationWashington University: Setting the Stage for Secondary Prevention Trials in Alzheimer Disease
Washington University: Setting the Stage for Secondary Prevention Trials in Alzheimer Disease John C. Morris, MD Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology Disclosure Statement
More informationChanging diagnostic criteria for AD - Impact on Clinical trials
Changing diagnostic criteria for AD - Impact on Clinical trials London, November 2014 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière Hospital
More informationCorporate Medical Policy Genetic Testing for Alzheimer s Disease
Corporate Medical Policy Genetic Testing for Alzheimer s Disease File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_alzheimers_disease 8/2010 10/2017 10/2018 10/2017
More informationNeuro degenerative PET image from FDG, amyloid to Tau
Neuro degenerative PET image from FDG, amyloid to Tau Kun Ju Lin ( ) MD, Ph.D Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital ( ) Department of Medical Imaging
More informationDISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
More informationAlzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia.
CHAPTER 3 Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia. This incurable, degenerative, terminal disease
More information#CHAIR2015. Miami, Florida. September 24 26, JW Marriott Miami. Sponsored by
#CHAIR2015 September 24 26, 2015 JW Marriott Miami Miami, Florida Sponsored by Case Challenge Workshop Alzheimer s Disease Anand Kumar, MD University of Illinois at Chicago, College of Medicine Chicago,
More informationRanjan Duara, MD, FAAN
Ranjan Duara, MD, FAAN Medical Director, Wien Center for Alzheimer s Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach Clinical Professor of Neurology, Herbert Wertheim College of Medicine,
More informationFirst US Plan to Address Alzheimer s Disease
First US Plan to Address Alzheimer s Disease Ronald C. Petersen, PhD, MD Chair Advisory Council on Research, Care and Services for the National Alzheimer s Project Act 2012 MFMER 3205603-1 NAPA Advisory
More informationAlzheimer s Disease without Dementia
Alzheimer s Disease without Dementia Dr Emer MacSweeney CEO & Consultant Neuroradiologist Re:Cognition Health London Osteopathic Society 13 September 2016 Early diagnosis of Alzheimer s Disease How and
More informationRoche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment
Roche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment Sunday 2 September 2018 Location: Shanghai, China NP/AZD/1807/0003 Complex
More informationThe added value of the IWG-2 diagnostic criteria for Alzheimer s disease
The added value of the IWG-2 diagnostic criteria for Alzheimer s disease Miami, January 2016 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière
More informationThe Aging Brain The Aging Brain
The Aging Brain The Aging Brain R. Scott Turner, MD, PhD Director, Memory Disorders Program Professor, Department of Neurology Georgetown University Washington, DC memory.georgetown.edu rst36@georgetown.edu
More informationUSE OF BIOMARKERS TO DISTINGUISH SUBTYPES OF DEMENTIA. SGEC Webinar Handouts 1/18/2013
Please visit our website for more information http://sgec.stanford.edu/ SGEC Webinar Handouts 1/18/2013 2013 WEBINAR SERIES STATE OF THE SCIENCE: DEMENTIA EVALUATION AND MANAGEMENT AMONG DIVERSE OLDER
More informationAlzheimer s disease is an
Alzheimer s Disease FACT SHEET Alzheimer s disease is an irreversible, progressive brain disease that slowly destroys memory and thinking skills, and eventually even the ability to carry out the simplest
More informationDiagnosis and Treatment of Alzhiemer s Disease
Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised
More informationWelcome to the Your Health Lecture Series!
Welcome to the Your Health Lecture Series! Tonight s Lecture: Alzheimer s Disease: A Look into the Future Moderator: Dr. Jean Nagelkerk Vice Provost for Health Grand Valley State University Event Begins
More informationTOWARD EFFECTIVE ALZHEIMER S THERAPY: PROGRESS AND COLLABORATION. Paul S. Aisen, MD Department of Neurosciences University of California, San Diego
TOWARD EFFECTIVE ALZHEIMER S THERAPY: PROGRESS AND COLLABORATION Paul S. Aisen, MD Department of Neurosciences University of California, San Diego Brief History of AD Therapeutics 1906: Dr. Alois Alzheimer
More informationProgress in Alzheimer s disease diagnostics validation and use of cognitive endpoints and surrogate markers
Progress in Alzheimer s disease diagnostics validation and use of cognitive endpoints and surrogate markers Randall Bateman, Tammie Benzinger, Nigel Cairns, John Morris, Nick Fox, Bill Klunk, Anne Fagan,
More informationAlzheimer s Disease Prevention Clinical Trials: Taking the Next Steps Responsibly. Joshua Grill University of California, Irvine
Alzheimer s Disease Prevention Clinical Trials: Taking the Next Steps Responsibly Joshua Grill University of California, Irvine Disclosures Site investigator for clinical trials sponsored by Avanir, Biogen
More informationCustom Intelligence. Alzheimer s Disease Landscape Summary
Custom Intelligence Alzheimer s Disease Landscape Summary Prepared August 21 Alzheimer s Disease Landscape: Executive Summary Current standard of care in Alzheimer s Disease (AD) consists of symptomatic
More informationNew diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist
New diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist Andrew E Budson, 1,2 Paul R Solomon 2,3 1 Center for Translational Cognitive Neuroscience, VA
More informationBiomarkers for Alzheimer s disease
Biomarkers for Alzheimer s Disease Henrik Zetterberg, MD, PhD Professor of Neurochemistry The Sahlgrenska Academy, University of Gothenburg 1 Alzheimer s disease 2 Neuropathological criteria for Alzheimer
More informationPocket Reference to Alzheimer s Disease Management
Pocket Reference to Alzheimer s Disease Management Pocket Reference to Alzheimer s Disease Management Anna Burke, MD Geriatric Psychiatrist, Dementia Specialist Geri R Hall, PhD, ARNP, GCNS, FAAN Advanced
More informationAlzheimer Disease Agents Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Alzheimer Disease Agents Drug Class Prior Authorization Protocol This policy has been developed through review
More informationIl processo diagnostico dell Alzheimer dalla clinica al neuroimaging Giovanni B. Frisoni M.D.
Il processo diagnostico dell Alzheimer dalla clinica al neuroimaging Giovanni B. Frisoni M.D. Professor of Clinical Neurosciences, University of Geneva Médecin Responsable, Memory Clinic, Hôpitaux Universitaires
More informationMolecular Imaging and the Brain
Molecular imaging technologies are playing an important role in neuroimaging, a branch of medical imaging, by providing a window into the living brain. Where CT and conventional MR imaging provide important
More informationNew Research on Neuraceq TM (florbetaben F18 injection) Imaging to be Presented at Annual Alzheimer s Association International Conference
Media Contacts: David Patti JFK Communications dpatti@jfkhealth.com (609) 241-7365 New Research on Neuraceq TM (florbetaben F18 injection) Imaging to be Presented at Annual Alzheimer s Association International
More informationAlzheimer's Disease A mind in darkness awaiting the drink of a gentle color.
Alzheimer's Disease A mind in darkness awaiting the drink of a gentle color. Mary ET Boyle, Ph. D. Department of Cognitive Science UCSD Gabriel García Márquez One Hundred Years of Solitude Alois Alzheimer
More informationIndiana University School of Medicine, Indianapolis, IN USA 1
GWAS and Candidate Studies of MRI and Amyloid PET Phenotypes for Alzheimer's Disease Andrew J. Saykin Depts. of Radiology & Imaging Sciences and Medical & Molecular Genetics, Neurology & Psychiatry; Indiana
More informationWhat s New in Dementia?
What s New in Dementia? Howard Rosen Professor, Department of Neurology UCSF and Aging Center Disclosure Biogen pharmaceuticals Small grant for clinical trials planning Dementia is a growing source of
More information11/12/2018. Acknowledgements. Risk factors for Alzheimer s disease
Is it Possible to Reduce My Risk for Alzheimer's Disease? An Overview of Current Risk Reduction Strategies Dorothy Farrar Edwards PhD, Professor of Medicine and Kinesiology Core Leader: Outreach, Recruitment
More informationPiramal Imaging to Present New Research in PET Imaging at Society of Nuclear Medicine and Molecular Imaging 2017 Annual Meeting
FOR IMMEDIATE RELEASE Media Contacts: Nicole Fletcher Piramal Imaging nicole.fletcher@piramal.com (857) 202-1122 Piramal Imaging to Present New Research in PET Imaging at Society of Nuclear Medicine and
More informationIssues to Consider in the Clinical Evaluation and Development of Drugs for Alzheimer s Disease. The University of Tokyo Hospital
Project to Promote the Development of Innovative Pharmaceuticals, Medical Devices, and Regenerative Medical Products (Ministry of Health, Labour, and Welfare) Regulatory Science Research for the Establishment
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationRe: Proposed Decision Memo for Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease (CAG-00431N)
1300 North 17 th Street Suite 1752 Arlington, Virginia 22209 Tel: 703.841.3200 Fax: 703.841.3392 www.medicalimaging.org July 26, 2013 By electronic mail Louis Jacques, MD Director Coverage and Analysis
More informationAlzheimer s disease prevention: from risk factors to early intervention
Crous-Bou et al. Alzheimer's Research & Therapy (2017) 9:71 DOI 10.1186/s13195-017-0297-z REVIEW Alzheimer s disease prevention: from risk factors to early intervention Marta Crous-Bou 1, Carolina Minguillón
More informationALZHEIMER S DISEASE FACTOIDS & STATISTICS
ALZHEIMER S DISEASE FACTOIDS & STATISTICS ~ 4 million affected in US alone 6-8% if 65+ years old, 30-50% if 80+ By 2030, in US >65 million people >65+ (---> ~14 million with AD) AD is one of the top 10
More informationCognitive Aging: Defining normal vs. disease?
Cognitive Aging: Defining normal vs. disease? Reisa Sperling, M.D. Harvard Aging Brain Study Center for Alzheimer Research and Treatment Brigham and Women s Hospital Massachusetts General Hospital Harvard
More informationEthical Issues in Alzheimer s Disease Clinical Trials: Genetic and Biomarker Disclosure
Ethical Issues in Alzheimer s Disease Clinical Trials: Genetic and Biomarker Disclosure Joshua Grill Associate Professor of Psychiatry and Human Behavior Alzheimer s Disease Research Center Institute for
More informationMild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
More informationAT RISK, SCI, EMCI: THE ALPHABET SOUP OF PRECLINICAL AND PRODROMAL ALZHEIMER DISEASE
AT RISK, SCI, EMCI: THE ALPHABET SOUP OF PRECLINICAL AND PRODROMAL ALZHEIMER DISEASE Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology Mary Quiceno, MD discloses she has received honoraria
More informationBrain imaging for the diagnosis of people with suspected dementia
Why do we undertake brain imaging in dementia? Brain imaging for the diagnosis of people with suspected dementia Not just because guidelines tell us to! Exclude other causes for dementia Help confirm diagnosis
More informationHow can the new diagnostic criteria improve patient selection for DM therapy trials
How can the new diagnostic criteria improve patient selection for DM therapy trials Amsterdam, August 2015 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM)
More informationDementia, Cognitive Aging Services and Support
Dementia, Cognitive Aging Services and Support Ronald C. Petersen, Ph.D., M.D. Professor of Neurology Mayo Clinic College of Medicine Rochester, MN NASUAD Washington September 2, 2015 Disclosures Pfizer,
More informationComments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic Guidelines? The Debate Continues
Comments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic s? The Debate Continues Ever since new criteria came out for a research diagnosis of prodromal/preclinical
More informationDr. Michael Lobatz Dr. Michael Jackson Dr. James Brewer Dr. Paul Aisen. Dr. Michael Plopper. Dr. Guerry Peavy
1 Anne State 2 3 Dr. Michael Lobatz Dr. Michael Jackson Dr. James Brewer Dr. Paul Aisen Dr. Michael Plopper Dr. Guerry Peavy 4 Michael Lobatz, MD Medical Director, Neurosciences Medical Director, Rehabilitation
More informationThe Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing
The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing. (AUSTRALIAN ADNI) July 2012 UPDATE Imaging Christopher Rowe MD Neuroimaging stream leader October 2011 The Australian Imaging Biomarkers
More informationConcept paper on no need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease and other dementias
15 March 20122 EMA/CHMP/60715/2012 Committee for Medicinal Products for Human Use (CHMP) Concept paper on no need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease
More informationRegulatory Challenges across Dementia Subtypes European View
Regulatory Challenges across Dementia Subtypes European View Population definition including Early disease at risk Endpoints in POC studies Endpoints in pivotal trials 1 Disclaimer No CoI The opinions
More informationDementia is not normal aging!
The Future of Alzheimer s Disease Treatment Adam L. Boxer, MD, PhD Director, Alzheimer s Disease Clinical Trials Program Memory and Aging Center Assistant Professor of Neurology University of California,
More informationThe Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing
The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing. (AUSTRALIAN ADNI) July 2013 UPDATE Imaging Christopher Rowe MD Neuroimaging stream leader June 2013 The Australian Imaging Biomarkers
More informationType 2 Diabetes and Brain Disease in Older Adults. Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky
Type 2 Diabetes and Brain Disease in Older Adults Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky Disclosures to Participants Requirements for Successful Completion: For successful completion,
More informationISCTM 2014 presentation
ISCTM 2014 presentation 20 Years of Clinical Trials in AD: Some Lessons Learned Pierre N. Tariot, MD Director, Banner Alzheimer's Institute Co-Director, Alzheimer s Prevention Initiative Research Professor
More informationMoving Targets: An Update on Diagnosing Dementia in the Clinic
Moving Targets: An Update on Diagnosing Dementia in the Clinic Eric McDade DO Department of Neurology School of Medicine Alzheimer Disease Research Center Disclosures No relevant financial disclosures
More informationMASSACHUSETTS ALZHEIMER S DISEASE RESEARCH CENTER
MASSACHUSETTS ALZHEIMER S THE NEWSLETTER DISEASE RESEARCH OF THE CENTER Volume 1, Issue 4 Winter 2010 http://madrc.mgh.harvard.edu/ Mild Cognitive Impairment (MCI) A new look at early changes MASSACHUSETTS
More informationALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey
ALZHEIMER S DISEASE Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey Topics Covered Demography Clinical manifestations Pathophysiology Diagnosis Treatment Future trends Prevalence and Impact
More informationAn integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease
An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease Angelica Quartino 1* Dan Polhamus 2*, James Rogers 2, Jin Jin 1 212, Genentech
More informationDementia and Healthy Ageing : is the pathology any different?
Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association
More informationMild Cognitive Impairment
Mild Cognitive Impairment Victor W. Henderson, MD, MS Departments of Health Research & Policy (Epidemiology) and of Neurology & Neurological Sciences Stanford University Director, Stanford Alzheimer s
More informationSecondary prevention of Alzheimer s dementia: neuroimaging contributions
ten Kate et al. Alzheimer's Research & Therapy (2018) 10:112 https://doi.org/10.1186/s13195-018-0438-z RESEARCH Open Access Secondary prevention of Alzheimer s dementia: neuroimaging contributions Mara
More informationBioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease
Press release BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in
More informationNovember 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by
November 16-18, 2017 Hotel Monteleone New Orleans, LA Provided by Treatment Targets in Alzheimer s Disease W. Vaughn McCall, MD, MS Professor and Case Distinguished University Chairman Department of Psychiatry
More informationEXPEDITION3: A Phase 3 Trial of Solanezumab in Mild Dementia due to Alzheimer s Disease
EXPEDITION3: A Phase 3 Trial of in Mild Dementia due to Alzheimer s Disease Lawrence S. Honig, MD, PhD On behalf of the EXPEDITION3 Study Team Disclosure Statement I will discuss investigational use only.
More informationA Dynamic Model of Care for Late Onset Cognitive Impairment. Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong
A Dynamic Model of Care for Late Onset Cognitive Impairment Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong Outline The pathogenesis of Late life cognitive impairment A framework
More informationClinical and Biomarker Changes in Dominantly Inherited Alzheimer s Disease
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Clinical and Biomarker Changes in Dominantly Inherited Alzheimer s Disease Randall J. Bateman, M.D., Chengjie Xiong, Ph.D., Tammie
More informationDIAN-TU Treatment Trials What s New with TU Sunday, September 21, 2014
DIAN-TU Treatment Trials What s New with TU Sunday, September 21, 2014 4:00 to 6:00 PM CDT Presented by Randall Bateman MD DIAN Trials Unit Director DIAN Clinical Core Leader Question and Answer Session
More informationYin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre
Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre Today Introduction to CT Introduction to MRI Introduction to nuclear medicine Imaging the dementias The Brain ~ 1.5
More informationDementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
More informationNeurocognitive Disorders Research to Emerging Therapies
Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia
More informationFOR IMMEDIATE RELEASE July 26, 2018 Eisai Co., Ltd. Biogen Inc.
FOR IMMEDIATE RELEASE July 26, 2018 Eisai Co., Ltd. Biogen Inc. EISAI AND BIOGEN ANNOUNCE DETAILED RESULTS OF PHASE II CLINICAL STUDY OF BAN2401 IN EARLY ALZHEIMER S DISEASE AT ALZHEIMER S ASSOCIATION
More informationOutline. Facts and figures Action plans Early / correct diagnosis Conclusions
Outline Facts and figures Action plans Early / correct diagnosis Conclusions Dementia: the greatest chalenge. Time to act now Philip Scheltens Professor of Neurology VU University Medical Center Amsterdam
More informationMemory Loss, Dementia and Alzheimer's Disease: The Basics
Memory Loss, Dementia and Alzheimer's Disease: The Basics What is memory loss? What is age-related memory loss? Typical changes Typical age-related changes involve: Making a bad decision once in a while
More informationToday s Conversation. What's New in Dementia Research and Care? Our vision is a world without Alzheimer s disease
Today s Conversation What's New in Dementia Research and Care? Heather M. Snyder, Ph.D. Medical & Scientific Relations Sam Fazio, Ph.D. Constituent Services Who We Are Alzheimer s Association International
More informationSUPPLEMENTARY INFORMATION In format provided by Frank et al. (JULY 2010)
Table 1 Imaging bios for Alzheimer s Visual rating High correlation with Multicenter studies have Accuracy for longitudinal hippocampus volume (R 2 been performed, but changes only at chance about 0.9,
More informationNew life Collage of nursing Karachi
New life Collage of nursing Karachi Presenter: Zafar ali shah Faculty: Raja khatri Subject: Pathophysiology Topic :Alzheimer s Disease Post RN BScN semester 2 nd Objective Define Alzheimer s Describe pathophysiology
More informationAlzheimer s disease (AD) is the most
Therapeutic development for Alzheimer s disease at Eli Lilly and Company AUTHORS Michael Hutton 1, Michael Irizarry 2, Mark Mintun 3, Phyllis Ferrell 2, Eric Siemers 2, Christer Nordstedt 2 & Ronald DeMattos
More informationThe current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease
The current state of healthcare for Normal Aging, g, Mild Cognitive Impairment, & Alzheimer s Disease William Rodman Shankle, MS MD FACP Director, Alzheimer s Program, Hoag Neurosciences Institute Neurologist,
More informationClinical Genetics & Dementia
Clinical Genetics & Dementia Dr Nayana Lahiri Consultant in Clinical Genetics & Honorary Senior Lecturer Nayana.lahiri@nhs.net Aims of the Session To appreciate the potential utility of family history
More informationRound table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation
Round table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation 1. Reflection of Mild Cognitive Impairment (MCI) and Dementias by Molecular Imaging, PET
More informationREFERENCE CODE GDHC98PIDR PUBLICATION DATE FEBRUARY 2015 ALZHEIMER S DISEASE GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC98PIDR PUBLICATION DATE FEBRUARY 2015 ALZHEIMER S DISEASE GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Table below presents the key metrics for Alzheimer s disease
More informationDIAN-TU Treatment Trials What s New with TU Sunday, April 13, 2014
DIAN-TU Treatment Trials What s New with TU Sunday, April 13, 2014 4:00 to 6:00 PM CDT Presented by Randall Bateman MD DIAN Trials Unit Director DIAN Clinical Core Leader Question and Answer Session 1
More informationCurrent Issues and Initiatives in Alzheimer s Research and Services. Disclosure. I have no relevant financial relationships to disclose
Current Issues and Initiatives in Alzheimer s Research and Services Carroll Rodriguez VP Public Policy and Communications Alzheimer s Association St. Louis Chapter 1 Disclosure I have no relevant financial
More informationFinding Solutions to the Alzheimer s Disease Epidemic in Indiana: Alzheimer s Research in Indiana
Finding Solutions to the Alzheimer s Disease Epidemic in Indiana: Alzheimer s Research in Indiana Bruce Lamb, Ph.D. Executive Director Stark Neurosciences Research Institute September 13, 2017 Critical
More informationDIAN-TU Treatment Trial UPDATE Webinar Sunday, March 1st, 2015
DIAN-TU Treatment Trial UPDATE Webinar Sunday, March 1st, 2015 4:00-6:00 PM CDT / 10:00 PM 12:00 AM GMT Presented by Randall Bateman MD Charles F. and Joanne Knight Distinguished Professor of Neurology
More information